Stock Snapshot
Price Performance
Recommendation Rationale
Favorable growth outlook supported by biosimilar launches and strategic investments.
Basis of our Recommendation
Biocon is poised for growth in FY27, driven by new biosimilar launches and enhanced capacity utilization. The company is also focusing on sustainable margins through strategic investments in R&D and a streamlined corporate structure, indicating a commitment to innovation and future demand.
Why We Like This Stock
- Strong growth anticipated from new biosimilar launches
- Improved capacity utilization enhancing operational efficiency
- Strategic investments in R&D indicating innovation potential
Things To Watch Out For
- nan
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 14,756 | 15,262 | 16,297 | 17,677 | 19,288 |
| Profit Before Tax (Cr.) | 1,469 | 1,840 | 851 | 1,030 | 1,095 |
| PBT Margin | 10.0% | 12.1% | 5.2% | 5.8% | 5.7% |
| Net Profit (Cr.) | 1,398 | 1,549 | 334 | 733 | 779 |
| EPS | 6.9 | 7.0 | 2.2 | 4.5 | 4.8 |
Company Overview
Show Company Profile
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.